BioSpace News Archive

Five Prime Therapeutics Inc., in collaboration Zai Lab Limited on the development bemarituzumab, a novel therapy for front-line advanced non HER2+ gastric or gastroesophageal junction (GEJ) cancer, on Wednesday announced groundbreaking positive topline Phase II results.

The company said they needed 53 patients in the study to be diagnosed with COVID-19, and the trial hit that figure yesterday.

InMode Ltd., a leading global provider of innovative medical technologies, announced consolidated financial results for its third quarter ended September 30, 2020.

Recommended Phase 2 Dose and Schedule Selected for Further Evaluation of RMC-4630 as Monotherapy and RMC-4630 plus Cobimetinib Combination

Translate Bio announced that the Company will participate in the following upcoming investor conferences:

Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2021 operating results on Tuesday, November 17, 2020 before the open of the U.S. financial markets. P

Plan to advance AXA1125 directly into a Phase 2b biopsy clinical trial in NASH under IND following successful Type B pre-IND meeting with FDA Plan to advance AXA1665 directly into a Phase 2 clinical trial in OHE under IND following positive top-line data from AXA1665-002 Published peer-reviewed manuscripts highlighting therapeutic benefit of EMMs and results from AXA1665-001 clinical study

Bioceres Crop Solutions Corp., a fully-integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, announced that it has entered into definitive agreements for the acquisition of the remaining 50% ownership interest in Verdeca LLC as well as strategic Intellectual Property assets related to soybean and wheat from Arcadia Biosciences Inc.

Danish drug formulation company ZERION announces the appointment of Dr. Wei Tian as Director of CMC development. He will join ZERION’s management team from November 2020.

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today reported financial results for its fiscal second quarter and six months ended September 30, 2020. Immunovant ended the quarter with approximately $444 million in cash. “Our team made outstanding operational and strategic progress during the fiscal second quarter,” said Pete Salzmann, M.D., Chief